Cwm LLC Has $104,000 Stock Holdings in Inogen, Inc (NASDAQ:INGN)

Cwm LLC grew its holdings in Inogen, Inc (NASDAQ:INGN) by 71.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,647 shares of the medical technology company’s stock after buying an additional 6,118 shares during the quarter. Cwm LLC’s holdings in Inogen were worth $104,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Inogen in the 1st quarter valued at $99,000. Tudor Investment Corp ET AL raised its stake in shares of Inogen by 44.9% in the 4th quarter. Tudor Investment Corp ET AL now owns 82,852 shares of the medical technology company’s stock valued at $760,000 after buying an additional 25,681 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Inogen by 5,738.9% in the 1st quarter. GAMMA Investing LLC now owns 5,547 shares of the medical technology company’s stock valued at $400,000 after buying an additional 5,452 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Inogen by 2.7% in the 4th quarter. Bank of America Corp DE now owns 127,326 shares of the medical technology company’s stock valued at $1,168,000 after buying an additional 3,304 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Inogen by 25.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock worth $5,574,000 after purchasing an additional 123,208 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Stock Performance

INGN opened at $6.55 on Thursday. The firm’s 50-day simple moving average is $6.73 and its 200-day simple moving average is $7.80. Inogen, Inc has a twelve month low of $5.70 and a twelve month high of $13.33. The firm has a market cap of $176.13 million, a price-to-earnings ratio of -5.70 and a beta of 1.66.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.27. Inogen had a negative net margin of 8.08% and a negative return on equity of 14.76%. The firm had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. As a group, sell-side analysts anticipate that Inogen, Inc will post -1.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on INGN shares. B. Riley started coverage on shares of Inogen in a report on Monday, June 16th. They issued a “buy” rating and a $14.00 target price on the stock. Stifel Nicolaus lowered their target price on shares of Inogen from $10.00 to $7.00 and set a “hold” rating on the stock in a report on Thursday, May 8th. Finally, Needham & Company LLC raised shares of Inogen from a “hold” rating to a “moderate buy” rating and set a $12.00 target price on the stock in a report on Thursday, May 22nd.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.